Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

This study has been terminated.
(PI left the institution)
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
Nationwide Children's Hospital
ClinicalTrials.gov Identifier:
NCT00639626
First received: March 14, 2008
Last updated: May 14, 2015
Last verified: May 2015

March 14, 2008
May 14, 2015
August 2008
May 2010   (final data collection date for primary outcome measure)
Blood sugar [ Time Frame: 6 months ] [ Designated as safety issue: No ]
To evaluate the effectiveness of Levemir to improve glycemic control in patients who have CFRD. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00639626 on ClinicalTrials.gov Archive Site
Lean body mass [ Time Frame: 6 months ] [ Designated as safety issue: No ]
To evaluate the metabolic effects of Levemir and the effect on body weight and lean tissue mass. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Use of Levemir® Improves Metabolic and Clinical Status in CFRD

This is a study to find out if Levemir® (a long acting or basal insulin) is safe and effective in treating cystic fibrosis related diabetes (CFRD).

Cystic fibrosis (CF) related diabetes (CFRD) and glucose intolerance affects more than 50%-75% of teens and adults with CF. The 1998 North American CF Foundation on CFRD categorized the disease differently than other types of diabetes: CFRD with fasting hyperglycemia (FH), CFRD without FH and transient CFRD. The outcome of this consensus conference was the use of insulin as the only recommended treatment of CFRD. Although the conference report mandated treatment for CFRD with FH, treatment was not mandated for the other types of CFRD, the choice to treat was left to the clinician's discretion. However, insulin was the only recommended therapy for all types of CFRD. Although some clinicians have used basal bolus regimens as the insulin management, many still use NPH. Given the need for CF patients to eat many frequent meals and snacks to maintain their weight, use of NPH insulin rarely renders good glycemic control. A basal bolus regimen is much more physiologic and would allow good glycemic control even with frequent meals and snacks. To date, there are no studies documenting safety and efficacy of true basal insulin, or a basal bolus regimen. Furthermore, protein catabolism and excessive muscle loss has been well documented in CF patients, both in those with and those without, glucose intolerance. Studies by our group and others have documented that a major reason for the catabolism is resistance to insulin's anti-catabolic effects on protein turnover. Thus, there is potential clinical benefit of improving muscle mass and general health by insulin treatment even for CF patients who do not have fasting hyperglycemia. A non-peaking basal insulin would be the only reasonable choice, yet studies are lacking. Our overall goal is to study the safety and efficacy of LevemirTM for the improvement of glycemic control of patients with CFRD. As a second goal, we will explore the ability of this basal insulin to improve protein catabolism and muscle mass. The study will be conducted as a six month trial.

Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cystic Fibrosis Related Diabetes
Drug: insulin detemir [rDNA origin] injection
Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
Other Name: Levemir
Experimental: Levemir
Intervention: Drug: insulin detemir [rDNA origin] injection

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients diagnosed with CFRD by oral glucose tolerance test (OGTT) who are medically stable. Medical stability will be defined as:

    • No hospital admission for six weeks or more before the study
    • No oral or intravenous antibiotics for at least six weeks preceding the study (subjects will be allowed to use low doses of inhaled corticosteroids).

Exclusion Criteria:

  • Use of oral or intravenous corticosteroid medications within six weeks of the study.
  • Evidence of clinically significant liver disease.
  • Colonization with Burkholderia cepacia.
  • Colonization with Aspergillus.
  • Pregnancy.
  • Medically unstable (stability defined above).
Both
16 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00639626
IRB07-00218
No
Nationwide Children's Hospital
Nationwide Children's Hospital
Novo Nordisk A/S
Principal Investigator: Dana S. Hardin, MD OSU, Nationwide Children's Hospital
Nationwide Children's Hospital
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP